Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients

J Pain Symptom Manage. 2010 Oct;40(4):545-58. doi: 10.1016/j.jpainsymman.2010.01.017. Epub 2010 Jun 25.


Context: The Patient Care Monitor (PCM) is a review of systems survey delivered by means of an electronic patient-reported outcomes (ePRO) data capture system that uses wireless tablet computers. Although the PCM 1.0 is validated, the updated PCM 2.0 has not been validated nor tested in the academic setting.

Objectives: To validate and test the PCM 2.0 in three cancer populations.

Methods: Two hundred seventy-five individuals participated in three clinical trials enrolling breast (n=65), gastrointestinal (n=113), and lung (n=97) cancer patients. Internal consistency was evaluated using Cronbach's alpha coefficients calculated for six PCM subscales (general physical symptoms, treatment side effects, distress, despair, impaired performance, and impaired ambulation) and a Quality-of-Life Index. Construct validity was evaluated through Pearson's correlation between PCM subscales and subscales of the Functional Assessment of Cancer Therapy--General (FACT-G), the M.D. Anderson Symptom Inventory (MDASI), and the Functional Assessment of Chronic Illness Therapy--Fatigue (FACIT-F). The participants had the following characteristics: mean age was 58 years (standard deviation: 11), 52% were females, 79% were whites, 17% were blacks, 62% had no college degree, and 78% had metastatic or recurrent disease.

Results: Raw and normalized scores for PCM 2.0 subscales were internally consistent across study cohorts. PCM 2.0 subscales correlated significantly (P<0.05) with the corresponding subscales on FACT-G, MDASI, and FACIT-F, with the exception of FACT-G social well-being, particularly for the lung cancer population. These correlations demonstrated construct validity. PCM 2.0 results followed expected patterns by cancer etiology. Prior reports demonstrate patient satisfaction with PCM 2.0.

Conclusion: Within three unique academic oncology populations, PCM 2.0 is a valid ePRO instrument for assessing symptoms with seven patient-centered subscale or index domains.

Publication types

  • Clinical Trial
  • Validation Study

MeSH terms

  • Aged
  • Breast Neoplasms / complications
  • Breast Neoplasms / physiopathology*
  • Breast Neoplasms / psychology
  • Data Collection / instrumentation
  • Data Collection / methods
  • Fatigue / complications
  • Fatigue / diagnosis
  • Fatigue / physiopathology
  • Fatigue / psychology
  • Female
  • Gastrointestinal Neoplasms / complications
  • Gastrointestinal Neoplasms / physiopathology*
  • Gastrointestinal Neoplasms / psychology
  • Health Status*
  • Humans
  • Lung Neoplasms / complications
  • Lung Neoplasms / physiopathology*
  • Lung Neoplasms / psychology
  • Male
  • Middle Aged
  • Pain / complications
  • Pain / diagnosis*
  • Pain / physiopathology
  • Pain / psychology
  • Pain Measurement / instrumentation
  • Pain Measurement / methods*
  • Patient Satisfaction
  • Quality of Life / psychology
  • Regression Analysis